NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to ...
The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector picked up in the past couple of months. This can be attributed to improved ...
MIT License Copyright (c) 2020 mhendriks Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation ...
Nektar Therapeutics (NASDAQ: NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...
Hosted on MSN
Soundcore Nebula P1 review: World's first portable theater system with detachable speakers!
British cardiologist shares two-word trick to lower blood pressure fast Akshaye Khanna asked Dhurandhar co-actor to slap him so hard, he falls: 'I was hesitant while beating up the senior actor' ...
With strong 1-year returns and upside potential, Nektar Therapeutics (NASDAQ:NKTR) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.
Nektar Therapeutics is advancing Rezpeg, a Treg-expanding biologic, in atopic dermatitis and alopecia areata, or AA, after regaining rights from Eli Lilly. Rezpeg demonstrated modest efficacy and good ...
SHENZHEN, China, Dec. 19, 2025 /PRNewswire/ -- One week after its Kickstarter debut, Anycubic's Photon P1 has attracted more than 1,200 backers and raised nearly US$880,000, signaling strong early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback